IN8bio appoints Dr. Trishna Goswami as Chief Medical Officer

IN8BIO, INC.

Annual base salary of $450,000; eligible for annual bonus targeted at 40% of base; signing bonus $10,000.
Awarded option to purchase 250,000 shares vesting over 4 years (25% at year 1).
Severance includes 12 months base salary, prorated target bonus, and 9 months COBRA if terminated without cause or for good reason.
Dr. Goswami previously led Trodelvy approvals at Gilead/Immunomedics; also worked at Stemline and AstraZeneca/MedImmune.
Appointment effective November 15, 2021.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Trishna Goswami

Chief Medical Officer

INAB · IN8BIO, INC.

Effective: 2021-11-15
Filed: November 17, 2021, 6:59 PM ET

Effective as of November 15, 2021, IN8bio, Inc. (the “ Company ”) appointed Dr. Trishna Goswami as the Company’s Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Trishna Goswami was appointed as Chief Medical Officer at IN8BIO, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Effective as of November 15, 2021, IN8bio, Inc. (the “ Company ”) appointed Dr. Trishna Goswami as the Company’s Chief Medical Officer.

View on SEC.gov

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-331409

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.